Jul. 1 at 10:04 PM
$RADX
As of late 2025, Lantheus owns a 14.5% equity stake in the company.
Initial & Mid-Stage Funding: Lantheus began collaborating with Radiopharm in mid-2024, eventually completing an A
$8 million (US
$5 million) private placement in January 2025 that brought its initial stake to 12.16%.Increased Position: In October 2025, Lantheus contributed an additional A
$7.6 million as part of a larger A
$35 million capital raise, bumping its total ownership to the current 14.5%.
This Relationship seems the most Logical for an Increasing Stake in this company buy Funding completely or Partially the Phase 3 Trial. Besides a Positive Read on a Phase Three would Likely Result in a Takeover.
